← Back to headlines
Eli Lilly Commits $2.88 Billion to Autoimmune Disease Portfolio Expansion
Pharmaceutical giant Eli Lilly is making a major strategic investment in autoimmune treatments, betting heavily on pipeline development despite potential regulatory hurdles and competitive market risks.
31 Aug, 23:44 — 31 Aug, 23:44
Sources
Showing 1 of 1 sources
